Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
SRG-514 by SURGE Therapeutics for Ductal Carcinoma In Situ: Likelihood of Approval
SRG-514 is under clinical development by SURGE Therapeutics and currently in Phase I for Ductal Carcinoma In Situ. According to...
SRG-514 by SURGE Therapeutics for Breast Cancer: Likelihood of Approval
SRG-514 is under clinical development by SURGE Therapeutics and currently in Phase I for Breast Cancer. According to GlobalData, Phase...
Resiquimod by SURGE Therapeutics for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer): Likelihood of Approval
Resiquimod is under clinical development by SURGE Therapeutics and currently in Phase II for Non Muscle Invasive Bladder Cancer (NMIBC)...